Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. M. (Hilde) Jalving

Publicaties

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma – Results of systematic literature research

128P - Whole blood transcriptomics identifies transcriptional patterns linked to outcomes in patients receiving immune checkpoint inhibitors

B cells critical for outcome in high grade serous ovarian carcinoma

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Desensitisatie als behandeloptie bij hypersensitiviteit voor antitumormedicijnen

Dosering van dexamethason rond pemetrexed kan lager

Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors: Data From a Prospective Study

Environmentally sustainable prescribing: recommendations for EU pharmaceutical legislation

Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo.

Lees meer

Pers/media

‘De cieDD is als voorbeeld gaan dienen voor de portal’

'NADINA-studie toegelicht door dr. Hilde Jalving'

MEDtalks - Melanoomupdate 2024

Environmental impact to be included in package leaflets accompanying medication

European Oncologists Are Thinking Green

“Green” prescribing may limit the environmental impact of oncology

MEDtalks E-learning; Zeldzame melanomen en huidtumoren

Lees meer